Last update 29 Aug 2025
Anwita Biosciences, Inc.

Anwita Biosciences, Inc.

Private Company|2018|California, United States|
10-50
|
www.anwitabio.com

Overview

Tags

Neoplasms
Skin and Musculoskeletal Diseases
Digestive System Disorders
Antibody fusion proteins
Antibody drug conjugate (ADC)
Biological products

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms9
Hemic and Lymphatic Diseases2
Immune System Diseases2
Top 5 Drug TypeCount
Antibody drug conjugate (ADC)5
Antibody fusion proteins2
Biological products1
Cytokines1
Top 5 TargetCount
IL-21R(Interleukin 21 Receptor)2
HER3(Receptor tyrosine-protein kinase erbB-3)1
LAG3(Lymphocyte activation gene 3 protein)1
IL-2R x PD-11
nectin-41

Related

9
Drugs associated with Anwita Biosciences, Inc.
Exenokine-21
Target
IL-21R
Mechanism
IL-21R agonists
Active Org.
Shanghai Junshi Biosciences Co., Ltd.Shanghai Junshi Biosciences Co., Ltd. [+2]
Originator Org.
Anwita Biosciences, Inc.Anwita Biosciences, Inc.
Active Indication
Neoplasms [+3]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
AWT-020
Target
IL-2R x PD-1
Mechanism
IL-2R agonists [+1]
Active Org.
Shanghai Junshi Biosciences Co., Ltd.Shanghai Junshi Biosciences Co., Ltd. [+1]
Originator Org.
Anwita Biosciences, Inc.Anwita Biosciences, Inc.
Active Indication
Advanced cancer [+13]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
RT-022
Target
EGFR x HER3
Mechanism
EGFR antagonists [+1]
Active Org.
Anwita Biosciences, Inc.Anwita Biosciences, Inc.
Originator Org.
Anwita Biosciences, Inc.Anwita Biosciences, Inc.
Active Indication
Non-Small Cell Lung Cancer
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Anwita Biosciences, Inc.
NCT06092580
/ RecruitingPhase 1
A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic Cancer
NCT05296772
/ RecruitingPhase 1
A Phase 1 Study of JS014, a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Cancer
100 Clinical Results associated with Anwita Biosciences, Inc.
Login to view more data
0 Patents (Medical) associated with Anwita Biosciences, Inc.
Login to view more data
1
Literatures (Medical) associated with Anwita Biosciences, Inc.
04 Aug 2023Cancer research communications
Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment
100 Deals associated with Anwita Biosciences, Inc.
Login to view more data
100 Translational Medicine associated with Anwita Biosciences, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
7
2
Phase 1
Other
12
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
AWT-020
 ( IL-2R x PD-1 )		Hepatocellular Carcinoma
More
Phase 1
Exenokine-21
 ( IL-21R )		Solid tumor
More
Phase 1
AWT030
 ( IL-21R )		Colonic Cancer
More
Preclinical
aLAG3-IL-2c(Anwita Biosciences)
 ( LAG3 )		Melanoma
More
Preclinical
HER3-ATI020
 ( HER3 )		Solid tumor
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free